AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy
Authors: Veal, GJ Dias, C Price, L Parry, A Errington, J Hale, J Pearson, ADJ Boddy, AV Newell, DR Tilby, MJ
Citation: Gj. Veal et al., Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy, CLIN CANC R, 7(8), 2001, pp. 2205-2212
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity
Authors: Smith, PG Thomas, HD Barlow, HC Griffin, RJ Golding, BT Calvert, AH Newell, DR Curtin, NJ
Citation: Pg. Smith et al., In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity, CLIN CANC R, 7(7), 2001, pp. 2105-2113
The impact of p53 status on cellular sensitivity to antifolate drugs
Authors: Lu, XH Errington, J Curtin, NJ Lunec, J Newell, DR
Citation: Xh. Lu et al., The impact of p53 status on cellular sensitivity to antifolate drugs, CLIN CANC R, 7(7), 2001, pp. 2114-2123
Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
Authors: Monks, NR Blakey, DC Curtin, NJ East, SJ Heuze, A Newell, DR
Citation: Nr. Monks et al., Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue, BR J CANC, 85(5), 2001, pp. 764-771
Flasks, fibres and flanks - pre-clinical tumour models for predicting clinical antitumour activity
Authors: Newell, DR
Citation: Dr. Newell, Flasks, fibres and flanks - pre-clinical tumour models for predicting clinical antitumour activity, BR J CANC, 84(10), 2001, pp. 1289-1290
A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation
Authors: Estlin, EJ Pinkerton, CR Lewis, IJ Lashford, L McDowell, H Morland, B Kohler, J Newell, DR Boddy, AV Taylor, GA Price, L Ablett, S Hobson, R Pitsiladis, M Brampton, M Clendeninn, N Johnston, A Pearson, ADJ
Citation: Ej. Estlin et al., A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation, BR J CANC, 84(1), 2001, pp. 11-18
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
Authors: Bowman, KJ Newell, DR Calvert, AH Curtin, NJ
Citation: Kj. Bowman et al., Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro, BR J CANC, 84(1), 2001, pp. 106-112
Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole
Authors: Marshman, E Taylor, GA Thomas, HD Newell, DR Curtin, NJ
Citation: E. Marshman et al., Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole, BIOCH PHARM, 61(4), 2001, pp. 477-484
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
Authors: Delaney, CA Wang, LZ Kyle, S White, AW Calvert, AH Curtin, NJ Durkacz, BW Hostomsky, Z Newell, DR
Citation: Ca. Delaney et al., Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines, CLIN CANC R, 6(7), 2000, pp. 2860-2867
Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines
Authors: Lu, XH Errington, J Chen, VJ Curtin, NJ Boddy, AV Newell, DR
Citation: Xh. Lu et al., Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines, CLIN CANC R, 6(1), 2000, pp. 271-277
Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presenceof alpha(1)-acid glycoprotein (AGP)
Authors: Barlow, HC Bowman, KJ Curtin, NJ Calvert, AH Golding, BT Huang, B Loughlin, PJ Newell, DR Smith, PG Griffin, RJ
Citation: Hc. Barlow et al., Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presenceof alpha(1)-acid glycoprotein (AGP), BIOORG MED, 10(6), 2000, pp. 585-589
Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group trial
Authors: Thomas, H Boddy, AV English, MW Hobson, R Imeson, J Lewis, I Morland, B Pearson, ADJ Pinkerton, P Price, L Stevens, M Newell, DR
Citation: H. Thomas et al., Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group trial, J CL ONCOL, 18(21), 2000, pp. 3614-3621
Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine
Authors: Griffin, RJ Arris, CE Bleasdale, C Boyle, FT Calvert, AH Curtin, NJ Dalby, C Kanugula, S Lembicz, NK Newell, DR Pegg, AE Golding, BT
Citation: Rj. Griffin et al., Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine, J MED CHEM, 43(22), 2000, pp. 4071-4083
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
Authors: White, AW Almassy, R Calvert, AH Curtin, NJ Griffin, RJ Hostomsky, Z Maegley, K Newell, DR Srinivasan, S Golding, BT
Citation: Aw. White et al., Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase, J MED CHEM, 43(22), 2000, pp. 4084-4097
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
Authors: Arris, CE Boyle, FT Calvert, AH Curtin, NJ Endicott, JA Garman, EF Gibson, AE Golding, BT Grant, S Griffin, RJ Jewsbury, P Johnson, LN Lawrie, AM Newell, DR Noble, MEM Sausville, EA Schultz, R Yu, W
Citation: Ce. Arris et al., Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J MED CHEM, 43(15), 2000, pp. 2797-2804
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
Authors: Monks, NR Calvete, JA Curtin, NJ Blakey, DC East, SJ Newell, DR
Citation: Nr. Monks et al., Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT), BR J CANC, 83(2), 2000, pp. 267-269
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel
Authors: Hughes, AN Griffin, MJ Newell, DR Calvert, AH Johnston, A Kerr, B Lee, C Liang, B Boddy, AV
Citation: An. Hughes et al., Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel, BR J CANC, 82(9), 2000, pp. 1519-1527
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport
Authors: Smith, PG Marshman, E Newell, DR Curtin, NJ
Citation: Pg. Smith et al., Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport, BR J CANC, 82(4), 2000, pp. 924-930
Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells
Authors: Barnes, MJ Taylor, GA Newell, DR
Citation: Mj. Barnes et al., Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells, BIOCH PHARM, 59(4), 2000, pp. 321-328
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines
Authors: Barnes, MJ Estlin, EJ Taylor, GA Aherne, GW Hardcastle, A McGuire, JJ Calvete, JA Lunec, J Pearson, ADJ Newell, DR
Citation: Mj. Barnes et al., Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines, CLIN CANC R, 5(9), 1999, pp. 2548-2558
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
Authors: Hughes, AN Rafi, I Griffin, MJ Calvert, AH Newell, DR Calvete, JA Johnston, A Clendeninn, N Boddy, AV
Citation: An. Hughes et al., Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days, CLIN CANC R, 5(1), 1999, pp. 111-118
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
Authors: Ghazal-Aswad, S Tilby, MJ Lind, M Baily, N Sinha, DP Calvert, AH Newell, DR
Citation: S. Ghazal-aswad et al., Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels, ANN ONCOL, 10(3), 1999, pp. 329-334
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growthinhibition by dipyridamole in human lung cancer cell lines
Authors: Smith, PG Marshman, E Calvert, AH Newell, DR Curtin, NJ
Citation: Pg. Smith et al., Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growthinhibition by dipyridamole in human lung cancer cell lines, SEMIN ONCOL, 26(2), 1999, pp. 63-67
Clinical pharmacokinetics of antitumor antifolates
Authors: Newell, DR
Citation: Dr. Newell, Clinical pharmacokinetics of antitumor antifolates, SEMIN ONCOL, 26(2), 1999, pp. 74-81
Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics
Authors: Newell, DR Burtles, SS Fox, BW Jodrell, DI Connors, TA
Citation: Dr. Newell et al., Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics, BR J CANC, 81(5), 1999, pp. 760-768
Risultati: 1-25 | 26-27